Tonix Pharmaceuticals Holding Corp (TNXP)
0.1587
0.00 (0.00%)
USD |
NASDAQ |
Apr 19, 16:00
0.1587
0.00 (0.00%)
After-Hours: 20:00
Tonix Pharmaceuticals Enterprise Value: -1.228M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | -1.228M |
| April 17, 2024 | -0.8073M |
| April 16, 2024 | -1.715M |
| April 15, 2024 | -2.097M |
| April 12, 2024 | -0.5111M |
| April 11, 2024 | 0.2054M |
| April 10, 2024 | 0.6641M |
| April 09, 2024 | 1.734M |
| April 08, 2024 | 1.686M |
| April 05, 2024 | 0.5303M |
| April 04, 2024 | 1.820M |
| April 03, 2024 | 2.928M |
| April 02, 2024 | 0.067M |
| April 01, 2024 | 0.0078M |
| March 28, 2024 | -2.324M |
| March 27, 2024 | 8.063M |
| March 26, 2024 | 3.599M |
| March 25, 2024 | 3.189M |
| March 22, 2024 | 4.244M |
| March 21, 2024 | 4.156M |
| March 20, 2024 | 4.953M |
| March 19, 2024 | 4.320M |
| March 18, 2024 | 3.511M |
| March 15, 2024 | 2.778M |
| March 14, 2024 | 3.441M |
| Date | Value |
|---|---|
| March 13, 2024 | 3.441M |
| March 12, 2024 | 3.306M |
| March 11, 2024 | 5.187M |
| March 08, 2024 | 5.914M |
| March 07, 2024 | 5.838M |
| March 06, 2024 | 5.463M |
| March 05, 2024 | 5.240M |
| March 04, 2024 | 6.184M |
| March 01, 2024 | 5.627M |
| February 29, 2024 | 6.131M |
| February 28, 2024 | 5.897M |
| February 27, 2024 | 5.533M |
| February 26, 2024 | 4.144M |
| February 23, 2024 | 2.837M |
| February 22, 2024 | 2.509M |
| February 21, 2024 | 4.472M |
| February 20, 2024 | 5.885M |
| February 16, 2024 | 6.324M |
| February 15, 2024 | 6.588M |
| February 14, 2024 | 6.588M |
| February 13, 2024 | 4.654M |
| February 12, 2024 | 5.650M |
| February 09, 2024 | 3.306M |
| February 08, 2024 | 3.30M |
| February 07, 2024 | 3.306M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-123.24M
Minimum
Dec 19 2022
570.77M
Maximum
Feb 11 2021
15.66M
Average
-0.4999M
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 2.374B |
| PetVivo Holdings Inc | 12.14M |
| Acurx Pharmaceuticals Inc | 26.09M |
| Kezar Life Sciences Inc | -134.13M |
| Allakos Inc | -77.65M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.32M |
| Revenue (Quarterly) | 3.779M |
| Total Expenses (Quarterly) | 31.11M |
| EPS Diluted (Quarterly) | -0.4661 |
| Gross Profit Margin (Quarterly) | 37.36% |
| Profit Margin (Quarterly) | -723.0% |
| Earnings Yield | -5.18K% |